Management of autoimmune and cholestatic liver disorders.
The management of autoimmune and cholestatic liver disorders is a challenging area of hepatology. Autoimmune and cholestatic liver diseases represent a comparatively small proportion of hepatobiliary disorders, yet their appropriate management is of critical importance for patient survival. In this article, management strategies are discussed, including the indications and expectations of pharmacologic therapy, endoscopic approaches, and the role of liver transplantation.
Krok
Karen L
KL
Division of Gastroenterology and Hepatology, University of Pennsylvania School of Medicine, 3400 Spruce Street, 3 Ravdin, Philadelphia, PA 19104, USA.
Munoz
Santiago J
SJ
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000209:etiology; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D015209:Cholangitis, Sclerosing / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D002908:Chronic Disease; D019693:Hepatitis, Autoimmune / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008105:Liver Cirrhosis, Biliary / Q000150:complications / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008113:Liver Neoplasms / Q000209:etiology; D016031:Liver Transplantation; D017410:Practice Guidelines as Topic; D011241:Prednisone / Q000627:therapeutic use; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D002756:Cholagogues and Choleretics; D007166:Immunosuppressive Agents; D014580:Ursodeoxycholic Acid; D001379:Azathioprine; D011241:Prednisone